Cost-Utility of Empagliflozin in Patients with Type 2 Diabetes at High Cardiovascular Risk

In the Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG) trial, empagliflozin reduced cardiovascular and all-cause mortality in type 2 diabetes (T2D) patients at high cardiovascular risk. We sought to estimate the cost-effectiveness of empagliflozin versus standard treatment for the prevention of cardiovascular morbidity and mortality in patients with T2D.
Source: Journal of Diabetes and Its Complications - Category: Endocrinology Authors: Source Type: research